Dow Drops More Than 1%; Nio Stock Declines Following Q2 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 02 2025
0mins
Should l Buy UTHR?
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones falling over 1%, while the NASDAQ and S&P 500 also experienced significant drops. Notable movements included a 2% decrease in NIO shares following disappointing quarterly results, despite a year-over-year revenue increase.
Sector and Commodity Updates: Consumer staples saw a slight increase, while information technology stocks fell. In commodities, oil and gold prices rose, and European and Asian markets mostly closed lower, reflecting a broader trend of declining equities globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to rise
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 531.820
Low
423.00
Averages
534.50
High
645.00
Current: 531.820
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SPMD Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: SPMD's 52-week low is $43.99 and high is $63.67, with the current trading price at $58.91, indicating stock price volatility near its high, which may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable technical insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs highlights those experiencing significant inflows or outflows, which not only affects the ETFs themselves but can also have substantial implications for the individual stocks held within them.
See More
Shift in Corporate Investments in DEI and ESG Initiatives
- Investment Trends: According to Just Capital's annual rankings, companies continue to increase investments in areas such as workers, communities, and the environment despite political and legal pressures, indicating a focus on long-term benefits.
- Employee Benefits Enhancement: Hewlett Packard stands out for its employee benefits, offering flexible time-off policies and 12 weeks of paid leave, aimed at improving employee economic well-being and job satisfaction.
- Minimum Wage Increase: The average minimum wage in the Russell 1000 has risen from $16.92 to $17.27, with more companies publicly disclosing their minimum wage, reflecting a growing emphasis on employee economic conditions.
- Decline in Transparency: While companies are ramping up investments in workforce initiatives, there has been a decline in disclosures related to diversity and climate issues, highlighting the complex balance companies face between external pressures and internal goals.
See More
Tyvaso® Study Shows New Hope for IPF Treatment
- Clinical Trial Results: The TETON-2 study demonstrated that Tyvaso® significantly improved absolute forced vital capacity (FVC) over 52 weeks, with a median change of -49.9 mL in the treatment group compared to -136.4 mL in the placebo group, resulting in a between-group difference of 95.6 mL (P<0.001), indicating its efficacy in IPF patients.
- Reduced Risk of Clinical Deterioration: Nebulized Tyvaso reduced the risk of clinical worsening events by 29% (hazard ratio 0.71, P=0.02), showcasing its potential in improving patient outcomes as evidenced by this statistically significant secondary endpoint.
- Representative Patient Characteristics: The study included 597 patients, with 75% on background antifibrotic therapy, reflecting the diverse characteristics of the IPF population, which underscores Tyvaso's antifibrotic properties across various patient subgroups.
- Future Regulatory Plans: United Therapeutics plans to submit a supplemental New Drug Application (sNDA) to the FDA by the second half of 2026, and if approved, Tyvaso will become the first inhaled antifibrotic treatment for IPF, marking a significant advancement in treatment options.
See More
Surge in Options Volume for AMD and UTHR
- AMD Options Volume: Today, AMD options have reached a trading volume of 359,964 contracts, representing approximately 36 million shares, which constitutes 96.6% of its average daily trading volume over the past month, indicating strong market interest in AMD stock.
- High-Frequency Contracts: Within AMD, the $170 strike put option has been particularly active, with 34,420 contracts traded today, equating to about 340,000 shares, suggesting an increased bearish sentiment among investors regarding future price declines.
- UTHR Options Activity: Concurrently, UTHR options have shown a volume of 3,679 contracts, representing approximately 367,900 shares, which accounts for 91.1% of its average daily trading volume over the past month, reflecting ongoing market interest in the stock.
- Key Contract Analysis: For UTHR, the $560 strike call option has seen 754 contracts traded, approximately 75,400 shares, indicating investor confidence in UTHR's potential price appreciation in the near future.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Middle East Tensions Impact Global Markets
- Market Decline: Wall Street opened the week in negative territory, with the S&P 500 falling 0.5% to around 6,700 points, reflecting investor concerns over Middle East tensions that could lead to increased market volatility.
- Rising Oil Prices: WTI crude oil surged about 6% to $97 per barrel, while Brent climbed to $98.31, although both benchmarks trimmed larger overnight gains in futures trading, indicating heightened worries over potential supply disruptions.
- Policy Response Expectations: U.S. President Trump is expected to announce measures to ease surging oil prices, including a coordinated release of strategic petroleum reserves by G7 countries, highlighting the seriousness with which major economies are addressing the risk of prolonged supply disruptions.
- Escalating Geopolitical Tensions: NATO intercepted an Iranian ballistic missile heading toward Turkey on Monday, signaling rising concerns that the regional conflict could expand, further increasing market uncertainty.
See More
SPMD Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: SPMD's 52-week low is $43.99 and high is $63.67, with the current trading price at $58.91, indicating stock price volatility near its high, which may influence investor buying decisions.
- Technical Analysis Tool: Comparing the current stock price to the 200-day moving average can provide valuable technical insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs highlights those experiencing significant inflows or outflows, which not only affects the ETFs themselves but can also have substantial implications for the individual stocks held within them.
See More
Shift in Corporate Investments in DEI and ESG Initiatives
- Investment Trends: According to Just Capital's annual rankings, companies continue to increase investments in areas such as workers, communities, and the environment despite political and legal pressures, indicating a focus on long-term benefits.
- Employee Benefits Enhancement: Hewlett Packard stands out for its employee benefits, offering flexible time-off policies and 12 weeks of paid leave, aimed at improving employee economic well-being and job satisfaction.
- Minimum Wage Increase: The average minimum wage in the Russell 1000 has risen from $16.92 to $17.27, with more companies publicly disclosing their minimum wage, reflecting a growing emphasis on employee economic conditions.
- Decline in Transparency: While companies are ramping up investments in workforce initiatives, there has been a decline in disclosures related to diversity and climate issues, highlighting the complex balance companies face between external pressures and internal goals.
See More
Tyvaso® Study Shows New Hope for IPF Treatment
- Clinical Trial Results: The TETON-2 study demonstrated that Tyvaso® significantly improved absolute forced vital capacity (FVC) over 52 weeks, with a median change of -49.9 mL in the treatment group compared to -136.4 mL in the placebo group, resulting in a between-group difference of 95.6 mL (P<0.001), indicating its efficacy in IPF patients.
- Reduced Risk of Clinical Deterioration: Nebulized Tyvaso reduced the risk of clinical worsening events by 29% (hazard ratio 0.71, P=0.02), showcasing its potential in improving patient outcomes as evidenced by this statistically significant secondary endpoint.
- Representative Patient Characteristics: The study included 597 patients, with 75% on background antifibrotic therapy, reflecting the diverse characteristics of the IPF population, which underscores Tyvaso's antifibrotic properties across various patient subgroups.
- Future Regulatory Plans: United Therapeutics plans to submit a supplemental New Drug Application (sNDA) to the FDA by the second half of 2026, and if approved, Tyvaso will become the first inhaled antifibrotic treatment for IPF, marking a significant advancement in treatment options.
See More
Surge in Options Volume for AMD and UTHR
- AMD Options Volume: Today, AMD options have reached a trading volume of 359,964 contracts, representing approximately 36 million shares, which constitutes 96.6% of its average daily trading volume over the past month, indicating strong market interest in AMD stock.
- High-Frequency Contracts: Within AMD, the $170 strike put option has been particularly active, with 34,420 contracts traded today, equating to about 340,000 shares, suggesting an increased bearish sentiment among investors regarding future price declines.
- UTHR Options Activity: Concurrently, UTHR options have shown a volume of 3,679 contracts, representing approximately 367,900 shares, which accounts for 91.1% of its average daily trading volume over the past month, reflecting ongoing market interest in the stock.
- Key Contract Analysis: For UTHR, the $560 strike call option has seen 754 contracts traded, approximately 75,400 shares, indicating investor confidence in UTHR's potential price appreciation in the near future.
See More
Oil Price Surge Drives Significant Stock Movements
- Oil Price Impact: Oil prices surged past $110 per barrel due to the ongoing Iran conflict, leading Chevron to hit an all-time high, while Talos Energy rose by 5%, and ConocoPhillips and Northern Oil gained 2% and 3% respectively, indicating strong performance among oil companies in a high-price environment.
- Hims & Hers Health Surge: The company's stock soared 39% after striking a deal with Novo Nordisk to sell its weight-loss drug, resolving a lawsuit over a copycat version, which is expected to significantly enhance its market share and brand reputation.
- Live Nation Settlement Near: Live Nation's shares rose 6% as it nears a settlement with the Department of Justice regarding monopoly allegations in the live concert industry, which, if successful, will stabilize and expand its future business operations.
- United Therapeutics Buyback Plan: The pharmaceutical company's shares increased by over 8% after its board authorized a $2 billion stock repurchase plan, with $1.5 billion allocated for accelerated buybacks, which is expected to boost investor confidence and enhance shareholder value.
See More
Middle East Tensions Impact Global Markets
- Market Decline: Wall Street opened the week in negative territory, with the S&P 500 falling 0.5% to around 6,700 points, reflecting investor concerns over Middle East tensions that could lead to increased market volatility.
- Rising Oil Prices: WTI crude oil surged about 6% to $97 per barrel, while Brent climbed to $98.31, although both benchmarks trimmed larger overnight gains in futures trading, indicating heightened worries over potential supply disruptions.
- Policy Response Expectations: U.S. President Trump is expected to announce measures to ease surging oil prices, including a coordinated release of strategic petroleum reserves by G7 countries, highlighting the seriousness with which major economies are addressing the risk of prolonged supply disruptions.
- Escalating Geopolitical Tensions: NATO intercepted an Iranian ballistic missile heading toward Turkey on Monday, signaling rising concerns that the regional conflict could expand, further increasing market uncertainty.
See More
